PHAXIAM Therapeutics S.A. (EPA:PHXM)

Market Cap	19.03M
Revenue (ttm)	2.14M
Net Income (ttm)	-21.92M
Shares Out	10.01M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,213
Average Volume	7,423
Open	1.890
Previous Close	1.870
Day's Range	1.858 - 1.900
52-Week Range	1.500 - 3.080
Beta	1.70
RSI	58.84
Earnings Date	Mar 13, 2025

About PHAXIAM Therapeutics

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thir...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 68
• Stock Exchange: Euronext Paris
• Ticker Symbol: PHXM

Financial Performance

In 2023, PHAXIAM Therapeutics's revenue was 1.33 million, a decrease of -80.05% compared to the previous year's 6.65 million. Losses were -23.49 million, 10201.8% more than in 2022.